267 related articles for article (PubMed ID: 21269333)
1. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
[TBL] [Abstract][Full Text] [Related]
2. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
3. Cell surface Nestin is a biomarker for glioma stem cells.
Jin X; Jin X; Jung JE; Beck S; Kim H
Biochem Biophys Res Commun; 2013 Apr; 433(4):496-501. PubMed ID: 23524267
[TBL] [Abstract][Full Text] [Related]
4. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
7. The stem cell marker nestin predicts poor prognosis in human melanoma.
Piras F; Perra MT; Murtas D; Minerba L; Floris C; Maxia C; Demurtas P; Ugalde J; Ribatti D; Sirigu P
Oncol Rep; 2010 Jan; 23(1):17-24. PubMed ID: 19956860
[TBL] [Abstract][Full Text] [Related]
8. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Chinnaiyan P; Wang M; Rojiani AM; Tofilon PJ; Chakravarti A; Ang KK; Zhang HZ; Hammond E; Curran W; Mehta MP
Radiat Oncol; 2008 Sep; 3():32. PubMed ID: 18817556
[TBL] [Abstract][Full Text] [Related]
10. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
11. Isolation and partial characterization of a new human glioblastoma cell line.
Brehar FM; Bleotu C; Stefan LM; Buzgariu W; Chivu M; Utoiu E; Matei L; Ciurea AV; Tascu A
Chirurgia (Bucur); 2009; 104(4):453-61. PubMed ID: 19886054
[TBL] [Abstract][Full Text] [Related]
12. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
13. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
14. Correlation between glioblastoma stem-like cells and tumor vascularization.
He H; Niu CS; Li MW
Oncol Rep; 2012 Jan; 27(1):45-50. PubMed ID: 21971709
[TBL] [Abstract][Full Text] [Related]
15. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
16. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
17. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.
Veselska R; Hermanova M; Loja T; Chlapek P; Zambo I; Vesely K; Zitterbart K; Sterba J
BMC Cancer; 2008 Oct; 8():300. PubMed ID: 18925963
[TBL] [Abstract][Full Text] [Related]
18. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
20. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
